The goal of this clinical trial is to learn if the ankle audiometry test performed with the B250 bone conduction transducer can identify patients with superior canal dehiscence syndrome from those without among subjects presenting with autophony (a hearing condition where you hear your own body sounds) and/or pulsatile tinnitus.
The main question it aims to answer:
• Can ankle audiometry performed with B250 identify the condition of superior canal dehiscence syndrome among patients with autophony and/or pulsatile tinnitus, with a significance level of 80% and power level of 15%?
Study participants will undergo ankle audiometry testing with the B250 and the threshold in dB FL (at the ankle) for which the patient hears the sound in the target ear will be measured.
Age between 18 and 64 years.
Patients with symptoms of autophony and/or pulsatile tinnitus either due to a confirmed diagnosis of SCDS or not due to SCDS.
Severe sensorineural hearing.
Middle ear or ear canal pathologies.
Vulnerable patients.
Confirmed intolerance or contraindication for body (ankle) vibratory stimulation.
Single group
Ankle audiometry performed with the B250 transducer
Diagnostic testCalibrated vibration stimulation with a frequency of 250 Hz is applied at the ankle with the B250 transducer starting at an intensity of 80 dB FL. An incremental increase/decrease in the intensity of the applied bone vibration stimulus is employed in a manner similar to that performed during a standard pure tone hearing test. This is done in order to find the threshold in dB FL (at the ankle) for which the patient hears the sound in the target ear (right) is measured. The maximum applied intensity at the ankle will be 140 dB FL.
The detection of SCDS among patients with autophony and/or pulsatile tinnitus.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
